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Tumor metabolism and associated
serum metabolites define
prognostic subtypes of Asian
hepatocellular carcinoma
Yotsawat Pomyen1,2,14, Anuradha Budhu1,3,14, Jittiporn Chaisaingmongkol1,4,5,
Marshonna Forgues1, Hien Dang1,6, Mathuros Ruchirawat4,5, Chulabhorn Mahidol4,
Xin Wei Wang1,3* & the TIGER-LC Consortium*
Treatment effectiveness in hepatocellular carcinoma (HCC) depends on early detection and precisionmedicine-based patient stratification for targeted therapies. However, the lack of robust biomarkers,
particularly a non-invasive diagnostic tool, precludes significant improvement of clinical outcomes
for HCC patients. Serum metabolites are one of the best non-invasive means for determining patient
prognosis, as they are stable end-products of biochemical processes in human body. In this study, we
aimed to identify prognostic serum metabolites in HCC. To determine serum metabolites that were
relevant and representative of the tissue status, we performed a two-step correlation analysis to
first determine associations between metabolic genes and tissue metabolites, and second, between
tissue metabolites and serum metabolites among 49 HCC patients, which were then validated in
408 additional Asian HCC patients with mixed etiologies. We found that certain metabolic genes,
tissue metabolites and serum metabolites can independently stratify HCC patients into prognostic
subgroups, which are consistent across these different data types and our previous findings. The
metabolic subtypes are associated with β-oxidation process in fatty acid metabolism, where patients
with worse survival outcome have dysregulated fatty acid metabolism. These serum metabolites may
be used as non-invasive biomarkers to define prognostic tumor molecular subtypes for HCC.
Hepatocellular carcinoma (HCC) is one of the leading cancers worldwide in both incidence and mortality.
According to the Global Cancer Observatory, the number of new liver cancer cases worldwide is 4.7% of all
cancer incidence but accounted for 8.2% of all cancer deaths in 2 0181. It is estimated that there will be a 64%
increase in incidence and a 69% increase in mortality of liver cancer by 2040 based on 2018 s tatistics2. Most of
these incidence and deaths will occur in East Asia and Southeast Asia, including Thailand.
In the past, Thailand had one of the highest incidence of HCC due to the high prevalence of hepatitis B virus
(HBV) infection3 and food contamination by aflatoxin B1 (AFB1)4,5. However, lifestyle changes and economic
improvement over several decades have shifted the cause of HCC from HBV infection and food contamination to
new causes, such as Hepatitis C virus (HCV) infection6 and non-alcoholic fatty liver disease (NAFLD)7,8. The shift
in the landscape of hepatocarcinogenesis is now a challenge for healthcare professionals. Currently, α-fetoprotein
(AFP) is the most convenient and non-invasive serum biomarker for detecting H
 CC9. However, the reliability
of AFP compared to ultrasound is still an ongoing debate for early-stage detection of the HCC10,11. Therefore,
there is an urgent need for better serum biomarkers to achieve early detection and better patient stratification
for precision oncology to improve patient p
 rognosis9,10.
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Previously, our group has shown that serum AFP alone is not sufficient as a biomarker for early detection or
patient stratification of aggressive HCC subtypes in Asian patient c ohorts12,13. With the shortcomings of AFP in
Asian populations, we have established a gene-signature panel of molecular subtypes that can consistently stratify
aggressive HCC and intrahepatic cholangiocarcinoma (iCCA) subtypes among several Asian p
 opulations13.
However, this and previous signatures, are mainly based on gene expression and miRNA expression signatures
derived from bulk tumor tissues, which are difficult to obtain without surgical resection of the t umors14. In this
study, we reasoned that the molecular subtype-related tumor biology may have a systemic impact and, therefore,
be reflected through the systemic serum metabolite profiles of the patients. To identify serum metabolites that
are surrogates of gene-based molecular subtypes, we employed metabolite-focused, two-step correlation analysis,
first with correlation analysis between tissue gene expression of metabolic genes and tissue metabolite profiles,
and second, between tissue metabolite profiles and serum metabolite profiles. This strategy allowed us to identify
serum metabolite panels that can stratify HCC patients according to their tumor-related prognostic subtypes.

Results

Tissue metabolites can distinguish between tumor and non‑tumor tissue. The overall flowchart

of the analysis strategy is illustrated in Fig. 1A, with a detailed analysis flowchart shown in Supplementary
Fig. S1. To test whether tissue metabolites can distinguish tumor and non-tumor tissues of 56 HCC patients,
Principal Component Analysis (PCA) was used to classify tissue samples based on metabolites measured by
an untargeted metabolomics approach (Fig. 1B). Based on the 500 metabolites with highest variability among
samples, tumor and non-tumor tissues can be separated clearly. To visualize the extent of tissue metabolites and
pathways that are dysregulated, differentially altered metabolites between tumor and non-tumor tissues were
overlaid onto overall human metabolite map from KEGG15. The 562 known detected tissue metabolites can
be converted to 352 KEGG compound IDs from the total of 1271 metabolites present on the map (accession
number hsa01100). The affected metabolites in HCC fall into four main metabolic categories, i.e., nucleotide
metabolism, amino acid metabolism, energy metabolism, and lipid metabolism (Fig. 1C).

Metabolic genes, tissue and serum metabolites can identify patients with worse survival outcome. We used metabolism-specific genes to further determine if they can classify HCC into prognostic

subtypes. To ensure that the metabolic genes and tissue metabolites are tumor-specific, we incorporated the
calculation of a paired t-test between tumor and adjacent non-tumor tissue gene expression. For the first step of
the correlation analysis, the numbers of metabolic genes and metabolites that passed correlation thresholds from
a permutation test and a paired t-test with an FDR-adjusted p-value of < 0.05 were 491 genes and 78 metabolites,
respectively (Supplementary Table S1). Among 78 metabolites that passed the correlation coefficient thresholds (Supplementary Table S2), 40 metabolites passed an additional 1.5 fold-change cutoff between tumor and
adjacent non-tumor tissues (Fig. 2A, Supplementary Fig. S2A, and Supplementary Table S3). We performed
hierarchical clustering analysis on Thai HCC patient samples by using consensus clustering algorithm16 based
on these 491 metabolic genes (MetGene) or 40 tumor-specific metabolites (TissueMet) which revealed three
stable clusters based on metabolic genes or tumor-specific tissue metabolites, named MetGene-C1, MetGeneC2, and MetGene-C3, or TissueMet-C1, TissueMet-C2, and TissueMet-C3, respectively (Fig. 2B—upper panel).
The metabolic gene expression based on 491 genes shows distinct expression patterns between the three clusters,
which are similar to previously identified common Asian subtypes (Fig. 2B—middle panel)13. Similar to global
transcriptome profiling analysis, there was no discernible pattern emerging from standard clinical and etiological parameters of HCC (Fig. 2B—lower panel). These results suggest that metabolic genes can capture major
molecular features of tumor samples. We also explored whether these subclasses were consistent with prognostic signatures published among HCC cohorts. To do so, we assessed S1-S3 signature17, stem cell signature18,
EpCAM signature19, Metastatic signature20, CCA-like signature21, Cluster 2 signature22, proliferation signature23
and found a concordance between the good and poor survival subclasses defined by the metabolic genes and
those defined by published signatures. We also performed consensus clustering using the same set of metabolic
genes in two other cohorts: Liver Cancer Institute (LCI)20 cohort and The Cancer Genome Atlas (TCGA)24
cohort on Asian patients only. Similar gene expression patterns were observed in both cohorts (Supplementary
Fig. S3A, B). The resulting MetGene clusters from LCI and TCGA cohorts were then subjected to Subclass
Mapping analysis to identify clusters that matched the original consensus clusters from the TIGER-LC cohort.
MetGene-C1 and MetGene-C2 clusters matched the original clusters from TIGER-LC cohort (Supplementary
Fig. S3C, D). To identify serum metabolites that are directly associated with tumor tissue metabolites, we performed a second step of correlation analysis between the 40 tumor-specific tissue metabolites and global serum
metabolites, which resulted in a set of 75 correlated serum metabolites (Fig. 3A and Supplementary Table S4).
Finally, to ascertain that the identified serum metabolites can stratify patients into similar subgroups as those
defined by metabolic genes and tumor tissue metabolites, we performed consensus clustering analysis based
on the 75 serum metabolites, which similarly yielded three stable clusters of the samples named SerumMetC1, SerumMet-C2, and SerumMet-C3. Similar to our assessment of metabolic genes, we found a concordance
between good and poor survival subclasses defined by the 75 serum metabolites and those defined by published
signatures.
We also investigated the mutation status of two genes that often mutated in HCC, namely TP53 and CTNNB1.
These two genes are not usually mutated together in the same patient. We found that TP53 mutation are predominantly in MetGene-C1, TissueMet-C1, and SerumMet-C1 clusters, whereas CTNNB1 mutation are predominantly found in MetGene-C3, TissueMet-C3, and SerumMet-C3 clusters (Fig. 2B—lower panel).
To determine whether the resulting patient subgroups are associated with patient outcome, survival analysis was performed. Survival analysis based on consensus clusters revealed that the C1 cluster from metabolic
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Figure 1.  Overall study design, tissue stratification by metabolite abundance and their related pathways. (A)
Overall flowchart of the analysis. (B) 3D PCA plot of tumor and adjacent non-tumor tissue metabolites from
Thai HCC patients based on expression of 500 most variable metabolites. The tumor and non-tumor tissues can
be clearly separated by tissue metabolites alone. (C) KEGG Overall Human Pathways (map accession number
hsa0110015) overlaid with metabolite ratios between tumor and adjacent non-tumor tissues from HCC patients.
Each node represents a human metabolite in a metabolic pathway. The colors represent log2 fold-change of the
tissue metabolites. Blue represents increased mean metabolite abundance from adjacent non-tumor tissues, and
red represents higher mean metabolite abundance from tumor tissues. White nodes represent metabolites with
no data available. Abbreviations: PCA—Principal Component Analysis; HCC—Hepatocellular Carcinoma.
genes (MetGene-C1), tissue metabolites (TissueMet-C1), and serum metabolites (SerumMet-C1) have similarly
worse survival outcome compared to other clusters (Fig. 3B–D, respectively). Hazard ratios [with 95% confidence interval (CI)] between the C1 cluster and other clusters defined by metabolic genes, tumor-specific tissue
metabolites, and serum metabolites are 5.8 [2.2–15], 3.3 [1–10], and 4.4 [1.6–12] respectively. The same trends
were also observed in the LCI and TCGA-Asian cohorts, however the C3 cluster was not present in either cohort
(Supplementary Fig. S3E, F). The C2 and C3 clusters from both metabolic genes and tissue metabolites of the
TIGER-LC cohort have similar survival trajectories (MetGene-C2 and MetGene-C3 in Fig. 3B, and TissueMetC2 and TissueMet-C3 in Fig. 3C), which should be expected since these metabolic genes and metabolites are
correlated. The trajectory of the C3 cluster in serum metabolites, however, did not resemble those of metabolic
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◂Figure 2.  Correlation analysis of tumor metabolic genes and tissue metabolites. (A) Heatmap of correlation

coefficients between 491 metabolic genes and 40 tumor-specific tissue metabolites that pass the thresholds of
0.165 and − 0.165 defined in by permutation test. (B) Heatmap of gene expression from 491 metabolic genes in
the tumor tissues from HCC patients from TIGER-LC cohort. The top panel of the heatmap shows clusters of
patients based on three classifications of patients: (1) the dendrogram is based on consensus clustering from
491 metabolic genes identified through permutation test (MetGene clusters); (2) common Asian subtypes
identified previously by our research group13; and (3) Tissue Metabolite (TissueMet) clusters, which are based
on consensus clustering from 40 tumor-specific tissue metabolites. The middle panel shows two heatmaps based
on z-score expression of 491 metabolic genes and 40 tumor-specific tissue metabolites. The bottom panel of
the heatmap shows mutation status of two genes (TP53 and CTNNB1), clinical features, and etiologies of each
tissue sample. Abbreviations: MetGene-C—Metabolic gene-Cluster; TissueMet-C—Tissue metabolite-Cluster;
HCC—Hepatocellular Carcinoma; BMI—Body Mass Index; TNM—TNM Classification of Malignant Tumors;
CA-19—Cancer Antigen 19–9; AFP—Alpha Fetoprotein; HBV—Hepatitis B virus; HCV—Hepatitis C virus;
OV—Opisthorchis viverrini. Each colored box above heatmap represents one sample. The color representing
“Good” prognosis and S3 signature is yellow, while “Poor” prognosis and S1 signature is represented by purple.
S2 signature is represented by green box.

genes or tissue metabolites clusters (Fig. 3D). Traditional prognostic biomarker for HCC, i.e., AFP > 300 ng/ml,
cannot separate patients into two subgroups with statistical significance in this cohort (Supplementary Fig. S4).
Hazard Ratio [95%CI] for AFP as prognostic biomarker in this cohort is 2 [0.72–5.5]. Interestingly, the samples that were classified as SerumMet-C1 using serum metabolites were predominantly C1 samples identified
by metabolic genes, tissue metabolites, and common Asian subtypes in our previous s tudy13, and the samples
from the C1 cluster classified by tissue metabolites are consistent with the C1 samples from serum metabolites
(Fig. 4A—upper panel). Similar to the consensus clusters identified using metabolic genes, there is no discernible
pattern associated with any cluster defined by the serum metabolites and standard HCC etiology parameters
(Fig. 4A—lower panel). Overall, serum metabolites were representative of metabolic genes and tissue metabolites
in their capacity to classify outcome-related molecular subgroups.

Identified serum metabolites are associated with fatty acid metabolism and secondary
metabolism of microbial metabolites. We next ascertained the pathways that were present and/or

altered among the metabolite-defined clusters. To do so, we performed pathway analysis based on the metabolic
gene expression among the MetGene clusters. When comparing the 491 metabolic gene expression between
samples from different MetGene clusters using Ingenuity Pathway Analysis (IPA)25, we found that the top three
pathways, namely lipid metabolism, i.e. LPS/IL-1 mediated inhibition of RXR function, fatty acid β-oxidation
I, and PXR/RXR activation, were deregulated in all the comparisons between the three MetGene clusters,
with − log10(p-values) of MetGene-C1/C2, MetGene-C1/C3, and MetGene-C2/C3 as 21.7, 24.4, and 21.7, respectively (Supplementary Fig. S5 and Supplementary Table S5). The results concurred with serum metabolite data,
where short-chain and long-chain acylcarnitines were differentially abundant among the three serum metabolite
clusters (Fig. 4A and Supplementary Fig. S6).
To further confirm that these dysregulated pathways based on gene expression levels are truly associated
with lipid metabolism, we determined the composition of the identified 75 serum metabolites by tabulating
the metabolites according to their classes and subclasses. Almost half (46%) of the identified serum metabolites
were lipids (Supplementary Fig. S2B), which consisting mainly of acylcarnitines (28%), phospatidylcholine and
lysophosphatidylcholine (PC and lysoPC—25%), while the remainder are other assorted lysolipids, steroids
and fatty acids (Supplementary Fig. S2C). One class of serum metabolites with highest abundance, namely
acylcarnitines, is strongly correlated with tissue metabolites (Fig. 4C, D) and reflect the pathway analysis based
on tumor and adjacent non-tumor matched tissue gene expression, with HNF4α as possible transcriptional
regulator (Supplementary Figs. S7A, B and S8). Notable metabolites from this class are short-chain acylcarnitines (butyrylcarnitine, 2-methylmalonyl carnitine, and glutarylcarnitine) and long-chain acylcarnitines (laurylcarnitine, myristoleoylcarnitine, and oleoylcarnitine). The median relative abundance levels in log10 of these
metabolites for SerumMet-C1, C2, and C3 are as follow: butyrylcarnitine—23.32, 23.44, 23.50; 2-methylmalonyl
carnitine—17.9, 18.25, 18.13; glutarylcarnitine—21.40, 21.81, 21.59; laurylcarnitine—21.0, 20.42, 18.23; Myristoleoylcarnitine—21.81, 21.67, 18.23; and Oleoylcarnitine—22.87, 22.92, 21.35. Acylcarnitines are intermediate
metabolites in fatty acid metabolism, specifically in process of fatty acid transportation from the cytosol to the
mitochondria during fatty acid β-oxidation whereby fatty acids are broken down. The next most abundant class
of serum metabolites is lysoPC, which constitutes the majority of biological membranes and is easily obtained
through the diet. Other metabolite classes were amino acids, xenobiotics, peptides, carbohydrates, cofactors and
vitamins, and energy metabolites. One other notable class of metabolites observed among the 75-serum metabolite set is microbial metabolites, which consisted of p-cresol sulfate (PCS), 4-ethylphenyl sulfate (4-EPS), and
4-methylcathechol (Fig. 4A, B, Supplementary Fig. S9 and Supplementary Table S5). The median relative abundance levels in log10 of these metabolites for SerumMet-C1, C2, and C3 are as follow: p-cresol sulfate—28.62,
26.95, 27.72; 4-ethylphenyl sulfate—23.84, 18.32, 21.05; and 4-mythylcatechol sulfate—22.64, 21.72, 22.51.
Finally, to determine whether clinical variables were associated with various subtypes identified in this study,
we performed a Fisher’s Exact test between these clinical variables and the subtypes. We found that most of
the clinical features are independent of these subtypes, with the two exceptions of AFP/MetGene subtypes and
BMI/SerumMet subtypes (Supplementary Table S5). The samples with AFP level > 300 ng/ml are clustered in
the MetGene-C1 subgroup, which has worse prognosis compared to other subgroups. The group with BMI > 24
(overweight patients) is linked with the SerumMet-C2 subgroup, which has better prognosis compared to other
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Figure 3.  Correlation analysis of tissue and serum metabolites. (A) Heatmap of correlation coefficients between
40 tumor-specific tissue metabolites and 75 serum metabolites identified in this study. (B) Kaplan–Meier plot
showing survival probabilities of HCC patients from TIGER-LC cohort according to consensus clustering based
on expression of 491 metabolic genes. (C) Kaplan–Meier plot showing survival probabilities of HCC patients
from TIGER-LC cohort according to consensus clustering based on abundance of 40 tumor-specific metabolites.
(D) Kaplan–Meier plot showing survival probabilities of HCC patients from TIGER-LC cohort according to
consensus clustering based on abundance of 75 serum metabolites. Abbreviations: HR [95% CI]—Hazard Ratio
with 95% confidence interval; MetGene-C—Metabolic gene-Cluster; TissueMet-C—Tissue metabolite-Cluster;
SerumMet-C—Serum metabolite-Cluster.
subgroups. This data concur with the notion that short-chain acylcarnitines in SerumMet-C2 subgroup have
the most abundant level among all the subgroups.
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Discussion

In this study, we present a set of serum metabolites that can potentially be used as non-invasive prognostic
biomarkers that are reflective of tumor-tissue status. The multiple levels of metabolite-related data can independently stratify Asian HCC patients into molecular subtypes that have similar patient outcomes. Compared to our
previous study that utilized whole transcriptome analysis to identify HCC molecular s ubtypes13, here, we have
considerably decreased the number of markers that are required for patient stratification without compromising
the subgroup consistency. Furthermore, the identified metabolic genes and metabolites gave new insights into
the molecular underpinnings of Asian HCC.
Serum metabolite measurement is a potential non-invasive tool for early detection and prognosis determination of HCC. Compared to other noninvasive techniques, such as ultrasonography, computed tomography, or
magnetic resonance imaging (MRI), serum metabolites are considerably less cumbersome in terms of implementation and results interpretation. Previous publications have identified several fatty acids and acylcarnitines in
serum and plasma as early detection and prognostic biomarkers of HCC, indicating that fatty acid metabolism
is universally dysregulated in HCC12,26–29. However, to our knowledge, there is no study which directly correlates
the chain of events between gene expression and metabolites from tumor tissues to serum. Our study therefore
may present a more accurate picture of the molecular underpinnings of HCC.
The methodology employed in this study, namely two-step correlation analysis by first correlating tissue gene
expression and metabolite and then correlating tissue metabolites and serum metabolites, has unique advantages
over single step correlation. This approach combines permutation-based correlation threshold selection with
correlation analysis to objectively identify correlated genes and metabolites. The approach also utilized tissue
gene expression, tumor tissue and serum metabolites to identify the plausible causal chain of events that should
directly reflect molecular processes from tumor tissues to tissue metabolites, and finally to serum metabolites.
To our knowledge, this is the first study that utilized these data in this way. This method, combined with gene
expression and metabolomics data, allows us to directly observe the chain of associations between gene expression and metabolites in tumor tissue, and between tumor tissue and serum metabolites. It enables us to see a
convergence of evidence from multiple levels of data, from which patient subgroups resulting independently
from metabolic gene expression, tissue, and serum metabolites had similar patient outcome.
The set of 75 serum metabolites was able to independently stratify patients into subgroups that were also
consistent with patient subgroups from metabolic gene expression, tumor tissue metabolites, and whole transcriptome from our previous study13. The consistency in these clustering results is another indicator that the
identified metabolic genes and metabolites are involved in the disease manifestation. Furthermore, the numbers
of genes and metabolites involved in sample stratification were significantly lower compared to our previous
study, which will be beneficial for further utilization of these genes and metabolites as prognostic biomarkers. Finally, serum metabolites are more accessible and less invasive than gene expression or metabolites from
tumor tissues, therefore they are more suitable as less invasive prognostic biomarkers for Asian HCC patients.
This set of serum metabolites can be validated in larger patient cohorts in the future to facilitate HCC patient
prognostication in clinical settings.
Lipids and fatty acid metabolism play central roles in all cancer types, including HCC30. Pathway analyses
based on the abundance of both tumor tissue and serum metabolites, combined with tissue gene expression,
indicated that lipid and fatty acid metabolism are among the top dysregulated metabolic pathways in HCC. The
roles of one class of fatty acid-related metabolites of interest, i.e., acylcarnitines, are slowly emerging in HCC.
Acylcarnitines are known as intermediate metabolites in β-oxidation of fatty acids in m
 itochondria31,32. Shortand medium-chain acylcarnitines largely reside in peroxisomes and produced mainly by liver and muscle33,34. A
recent study showed that acylcarnitine profiles can be used as biomarkers for obesity-driven HCC, pinpointed
a serum metabolite, oleoylcarnitine (C18:1 carnitine), which was found in this study, as one of the biomarkers for NAFLD and HCC, and revealed the mechanism of actions of oleoylcarnitine through STAT3 pathway
activation31. The same study also identified several other acylcarnitines that were also identified in this study,
namely laurylcarnitine (C12:0) and myristoleoylcarnitine (C14:1), as possible HCC biomarkers. For short- and
medium-chain acylcarnitines, the evidence of the involvement in HCC are limited. Possible master regulators
for these metabolites are HNF4α, which were found in the pathway analysis and interacts with CPT1 and CPT2.
HNF4α was found to be the main regulator for acylcarnitines in brown adipose tissue in mice, in which the
brown tissue increases the uptake of acylcarnitines during the cold35. This will need further analyses to confirm
the actual link between HNF4α and acylcarnitines in human HCC.
The gut microbiome has been shown to play several important roles in liver diseases. Several mechanisms
involving the gut microbiome have been proposed, along with approaches to mitigate, prevent, or even reverse
HCC36. Many essential metabolites and nutrients are produced by gut microbes to provide precursors for more
complex molecules in human, such as hormones, vitamins, and other cofactors. Some metabolites identified in
this study, i.e., 4-EPS and PCS, are microbial metabolites derived from the diet37. Several studies found that PCS
is a highly potent uremic t oxin38 and can induce cell proliferation and migration of kidney c ancer39. The roles
of these compounds in HCC are still obscure. p-cresol is produced mainly by Clostridioides difficile (also known
as Clostridium difficile or C. diff)40. A recent study predicted that there may be other microbes which can also
produce p-cresol, but this needs to be c onfirmed41. p-cresol is metabolized in the liver through a conjugation
process, i.e. sulfonation, to produce a less toxic form, PCS42. There are several possible mechanisms that might be
specifically linked to PCS. It was found through molecular docking simulations that PCS can activate epidermal
growth factor receptor (EGFR) via interdomain pocket interaction of extracellular EGFR, and finally induce
kidney tissue remodeling43. A recent study showed that EGFR signaling promotes survival of HCC cell lines via
interaction with E-cadherin and β-catenin, but only in late stages of the disease44. Another possible mechanism is
that PCS might increase liver detoxification burden, especially sulfonation, affecting the ability of liver to detoxify
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◂Figure 4.  Patient clustering by serum metabolites and identification of prognostic serum metabolites.

(A) Heatmap of metabolite abundance from three selected groups of metabolites of interest: short-chain
acylcarnitines; long-chain acylcarnitines; and microbial metabolites. The top panel is patient clusters based on
various consensus clustering results: first row is consensus clustering results based on 75 serum metabolites;
second row is consensus clustering results based on 491 metabolic genes; third row is the original consensus
clustering of TIGER-LC HCC samples; and fourth row is consensus clustering results based on 40 tumor-tissue
metabolites. (B–D) Log-scale metabolite abundance. (B) Microbial metabolites (p-cresol sulfate, 4-ethylphenyl
sulfate, and 4-methylcatechol sulfate). (C) Short-chain acylcarnitines (Butyrylcarnitine [C4:1], 2-methylmalonyl
carnitine [C4-DC] and Glutarylcarnitine [C5-DC]). (D) Medium- (laurylcanitine [C12:1]) and long-chain
acylcarnitines (Myristoleoylcarnitine, [C14:1] and Oleoylcarnitine [C18:0]. The y-axis is the log10 metabolite
abundance. The x-axis is the SerumMet clusters. Abbreviations: MetGene-C—Metabolic gene-Cluster;
TissueMet-C—Tissue metabolite-Cluster; SerumMet-C—Serum metabolite-Cluster; HCC—Hepatocellular
Carcinoma.

other highly potent liver toxins, such as acetaminophen (paracetamol) or a flatoxin45. This study also proposed
a less invasive means for measuring PCS through urine in HCC patients45. PCS may also be associated with the
microbiome in that PCS-producing C. diff was found to be dominating in the gut of mice, due to toxicity of PCS
to other bacterial species in the gut46 and may be the mechanism of action of dysbiosis from C. diff infection.
Therefore, PCS might be a key link between gut dysbiosis and HCC pathogenesis.
Biomarker discovery for HCC is an active field of research. The metabolites mapped onto the KEGG’s Human
Metabolism Map in Fig. 1C were previously found to be dysregulated in HCC and have been proposed as either
prognostic or diagnostic biomarkers, but independently they were not able to outperform traditional HCC biomarkers. To further explore these dysregulations, we have assessed tumor specific metabolic gene alterations and
serum alterations and determined their association with clinical features including patient outcome. The specific
alterations and how they apply to HCC tumorigenesis would require detailed molecular and functional studies
which could be addressed in future studies. Numerous studies have been conducted to search for suitable serum
biomarkers that can predict survival outcome of patients in different populations47–50. Currently, however, clinically accepted prognostic serum biomarkers are limited to only α-fetoprotein (AFP), AFP-L3, and Des-γ-carboxy
prothrombin (DCP)51,52. Various acylcarnitines were suggested as serum or plasma biomarkers in several Asian
HCC cohorts, but none of these biomarkers have been validated in any clinical t rials29,53,54. The main reason for
this may result from the inconsistency of the data from these studies. One study of PCS suggests that it could
be a urine-based biomarker for differentiating HCC and cirrhotic patients. However, the study found that HCC
patients have lower PCS level compared to cirrhotic patients and suggested that sulfonation alteration might
be responsible mechanisms55. Thus, additional comprehensive studies are needed to determine the consistency
and effectiveness of such biomarkers.
In conclusion, we have established stable metabolic subtypes based on metabolic gene expression, tissue
metabolites and importantly, serum metabolites, through a two-step correlation analysis. Metabolic gene subtypes
can stratify patients into better and worse prognosis based on the metabolic gene expression across different
Asian patient cohorts. Tissue and serum metabolites can also consistently stratify patients into subgroups similar
to the metabolic gene subtypes and our previously identified common molecular Asian transcriptome-defined
subtypes. Some of the serum metabolites that we identified might serve as prognostic biomarkers after future
clinical validation. Validation in other cohorts should be a priority to translate this finding into clinical use.
Publicly available resource with both gene expression and serum metabolite measurement are not currently
available to further validate our findings. If and when such resources are available, we should have clearer picture of the serum metabolites associated with HCC. Finally, future studies that link metabolic alterations with
disease etiologies and clinical features would be of future interest to shed light on the underlying mechanisms
contributing to HCC which could be utilized in clinical management.

Methods

Cohorts, clinical, and genomic data. Tissue gene expression of the TIGER-LC cohort13, LCI c ohort20

and TCGA liver cohort24, were used this analysis. The list of metabolic genes (3765 genes) were retrieved from
Human Metabolic Reaction 2.0 (HMR2.0) d
 atabase56. Tissue metabolite data were described previously among
13
the TIGER-LC cohort . In brief, metabolites were measured in tumor tissues and serum using Metabolon’s
Discover HD4 Platform, which is an untargeted metabolomics approach that combines positive and negative
modes of liquid chromatography (LC+/LC−) and gas chromatography/mass spectrometry (GS/MS) to measure
metabolite abundance. After data processing, 718 and 990 metabolites were detected from tumor tissues and
serum samples, respectively. After excluding unidentified metabolites (metabolites that cannot be matched to
standard library compounds), there were 562 and 615 metabolites remaining for further analyses from tumor
tissues and serum, respectively. Clinical features data included in this study are
1.
2.
3.
4.
5.
6.
7.
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(2021) 11:12097 |

Mutation status of TP53 and CTNNB1 genes, determined in our previous s tudy13
Sex
Age, with two categories of <  = 50 and > 50 years old
Body Mass Index (BMI), with two categories of BMI <  = 24 and BMI > 24
Diabetes status, with two categories of no diabetes and with diabetes
CA-19–9 level, with two categories of CA-19–9 <  = 37 U/ml and CA19-9 > 37 U/ml
AFP level, with two categories of AFP <  = 300 ng/ml and AFP > 300 ng/ml
https://doi.org/10.1038/s41598-021-91560-1
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8.
9.
10.
11.
12.

Cirrhosis status, with two categories of Cirrhosis Positive and Cirrhosis Negative
TNM classification of malignant tumors, with two categories of early stage I and II, and late stage of IIIA,
IIIB, and IV
Hepatitis B virus (HBV) infection status, with two categories of HBV Positive and HBV Negative
Hepatitis C virus (HCV) infection status, with two categories of HCV Positive and HCV Negative
Orpisthorchis viverrini (OV) or liver fluke infection status, with two categories of OV Positive and OV
Negative

3D PCA of tissue metabolites. Three-dimensional principal component analysis projections of tumor
and adjacent non-tumor tissue metabolites were constructed based on the 500 most variable metabolites. The
most variable metabolites were selected based on variance of each metabolites among all HCC samples.
KEGG human and microbial metabolic maps. The KEGG map overlay with metabolite ratio was per-

formed using the R package pathview57. The metabolite names are converted to KEGG compound IDs, and
the maps required are downloaded through KEGG API by KEGGREST package in R58. The tissue metabolites
from the TIGER-LC cohort were overlaid onto the KEGG human metabolite m
 ap15 (map accession number:
hsa01100, retrieved on April 5, 2017) and reconstructed based on the TIGER-LC tissue metabolite ratio between
the mean of tumor tissues and adjacent non-tumor tissues. The log2-ratio of metabolites between tumor and
adjacent non-tumor tissues were calculated and used for map overlay. The serum metabolites were overlaid onto
the KEGG Microbial Metabolism in Diverse Environments map (map accession number: KO01120, retrieved
on April 10, 2021) and reconstructed based on the serum metabolite ratio between samples from SerumMet-C1
and SerumMet-C2 clusters.

Two‑step correlation analysis and correlation coefficient threshold selection by permutation analysis between metabolic gene expression, tissue metabolites, and serum metabolites. There are 3765 genes classified as human metabolic genes according to Human Metabolic Atlas database

version 2.059, of which approximately 2000 genes overlapped with the gene expression data from our previous
study13. Metabolic gene expression between tumor and adjacent non-tumor tissue were compared using a paired
t-test. The resulting p-values were adjusted using Benjamini–Hochberg false discovery rate (FDR) procedure60.
Metabolic genes with FDR-adjusted p-values of less than 0.05 were retained for further correlation analysis.
Spearman correlation coefficients between the expression of 2300 metabolic genes from tumor tissues and 562
metabolites from the TIGER-LC cohort were calculated.
For correlation threshold selection, the gene names, metabolite names, and the sample names in both metabolic genes and metabolite matrices were permutated to destroy original relationships of the original data. Then,
the correlation coefficient between permutated metabolic gene expression and metabolites were calculated and
recorded with 10,000 permutations. The distribution of correlation coefficients from the original data was plotted
against the average of distributions of correlation coefficients from the permutated data. Finally, the intersection
points of correlation coefficients between the original data and the average of permutated data was determined
to be -0.165 and 0.165 (Supplementary Fig. S10) and were used as correlation coefficient thresholds to select the
correlation coefficients between metabolic genes and metabolites for further analyses.
The metabolic genes and tissue metabolites were selected by calculating the average value of the sum of
absolute correlation coefficients from the following equations:
J  
I  
 
cji 
j=1 cij
Gi =
and Tj = i=1
J
I
where |cij| and |cji| are absolute correlation coefficient between metabolic gene i and tissue metabolite j, I is total
number of metabolic genes, J is total number of tissue metabolites, Gi is the average value of sum of absolute
correlation coefficients of metabolic gene i over tissue metabolites, and Tj is the average value of sum of absolute
correlation coefficients of tissue metabolite j over all metabolic genes. G and T that are higher than the correlation
coefficient threshold identified by permutation test are then selected for further analyses.
For the first step of correlation, the number of metabolic genes and tissue metabolites from correlation
coefficient threshold selection is 491 genes and 78 metabolites, respectively. Tissue metabolites that are tumorspecific was determined based on a metabolite fold-change of 1.5 between tumor and non-tumor adjacent tissues, which yielded 40 tumor-specific tissue metabolites that were used in the second step of correlation with
serum metabolites.
For the second step of correlation, correlation thresholds used for correlation analysis between tissue and
serum metabolites are − 0.15 and 0.15. These thresholds correspond to the sums of correlation coefficients
between tumor tissue gene expression and tissue metabolites previously identified. Serum metabolite selection,
the same strategy of average of the sum of absolute correlation coefficient is used, following the equation:
M
|ckm |
Sk = m=1
M
where |ckm| is absolute value of correlation coefficient between serum metabolite k and tumor-specific tissue
metabolite m, M is total number of tumor-specific tissue metabolites, and Sk is average value of sum of absolute
correlation coefficient of serum metabolite k over all tumor-specific tissue metabolites. The final number of serum
metabolites that passed the threshold is 75 metabolites.
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Consensus clustering analysis and subclass mapping analysis.

To define consensus clusters for the
patient samples among the Thai cohort, the matrix of 491 metabolic genes was used as the input for consensus
clustering61. Two other cohorts were used to validate identified metabolic genes, namely TCGA-LIHC24 and
LCI20 cohorts. The TCGA-LIHC cohort is comprised of liver cancer patients from across US cancer centers
as a part of The Cancer Genome Atlas project. The LCI cohort is comprised of Chinese liver cancer patients
from the Liver Cancer Institute. In our previous study we found that Asian patients had common molecular
features, which are different than patients with European or African d
 escent13. Therefore, in this study we only
used Asian descent samples from TCGA-LIHC. The data matrices from these two cohorts were obtained by
using the original 491 genes from the TIGER-LC cohort analysis and identifying the overlapping genes from
the TCGA-LIHC or LCI data sets. The LCI cohort has 385 overlapping genes, while TCGA-LIHC cohort has
461 overlapping genes. Consensus clustering was performed by using C
 onsensusClusterPlus16 package version
1.38 in R version 3.3.3. The reason for using consensus clustering in this study is to determine whether the
sets of metabolic gene expression, tumor tissue, and serum metabolites can independently stratify patients into
subgroups that have similar consistency amongst different molecular data types. The parameters used in all the
analyses were as follows: maxK = 8, number of bootstrap = 20,000; item subsampling proportion = 0.8; feature
subsampling proportion = 1; cluster algorithm = hc [hierarchical clustering]; inner linkage type = ward.D; final
linkage type = ward.D; correlation method = spearman; seed = 3044. The final number of clusters (k) selected for
further analyses is three.
The clustering results from the LCI and TCGA-Asian cohorts were then subjected to Subclass Mapping
(SubMap)62 analysis to determine whether the clusters from these two cohorts matched the clusters from the
TIGER-LC cohort. SubMap version 7.0 from GenePattern software s uite63 was used with default parameters. After
two-step correlation analysis, the list of 40 tumor-specific tissue metabolites and 75 serum metabolites were also
used for consensus clustering with the same parameters previously described to confirm that the metabolites
identified by correlation analysis can independently and consistently stratify patients into similar subgroups.
Submap analysis was also used to determine the if the TIGER-LC samples matched with other HCC signatures.
The HCC signatures used in this study were S1-S3 signature based on WNT-TGFβ, AKT-MYC signaling pathway activation, and hepatocyte d
 ifferentiation17, stem cell signature based on expression of stem cell gene set18,
EpCAM signature based on a gene set that is co-expressed with EpCAM19, metastatic signature based on a gene
set related to metastasis of HCC20, CCA-like signature based on a gene set from cholangiocarcinoma-like HCC21,
Cluster 1 and 2 signatures based on 238-gene signature from CCA patients22, and proliferation signature based
on copy number alterations and activation of oncogenic p
 athways23.

Statistical and survival analyses. All statistical and survival analyses were performed using R statistical
computing software version 3.3.3. Survival analysis on all cohorts was performed using a Kaplan Meier estimator and a Cox proportional hazards model was calculated between the worst survival group and the rest of the
groups, accompanied with Log-rank p-value for each comparison. The Cox proportional hazard assumption was
tested and met for all the tests carried out. The Paired t-test was used to calculate differential gene expression
between tumor and adjacent non-tumor tissues. All p-values are two-sided p-values unless otherwise stated and
adjusted for false discovery rate by Benjamini–Hochberg FDR procedure64.
Pathway analyses. The final 491 metabolic genes were subjected to pathway analyses using G
 SEA65 ver-

sion 18 on GenePattern software suite63 for tumor vs non tumor comparison, and Ingenuity Pathway Analysis
(IPA)66 version 01-16 for tumor clusters comparison.
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